Ishaque Hameed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ishaque Hameed has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
Khushboo Nusrat
Department of Medicine, University at Buffalo-Catholic Health System, Buffalo, NY
3 shared publicationsAshnah Aijaz
Dow Univ Hlth Sci, Dept Internal Med, Karachi, Pakistan
2 shared publications- Ibtehaj Ul-Haque
Internal Medicine, Dow University of Health Sciences, Karachi, PAK
2 shared publications Kaneez Fatima
Baylor, Scott & White Research Institute, Dallas, TX, USA
2 shared publicationsMohammad Arham Siddiq
Jinnah Sindh Med Univ, Dept Med, Karachi, Pakistan
2 shared publicationsMohammad Omer Khan
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
2 shared publications
Latest Publications
- 13 December 2025
- Published by Elsevier in Journal of Cardiology
- Vol. 87 (3) , 290-291
Prognostic implication of outpatient worsening heart failure in patients with transthyretin cardiac amyloidosis: A systematic review and meta-analysis
- 13 December 2025
- Published by Elsevier in Journal of Cardiology
- Vol. 87 (3) , 290-291
Prognostic implication of outpatient worsening heart failure in patients with transthyretin cardiac amyloidosis: A systematic review and meta-analysis
- Open Access
- 11 December 2025
- Published by Elsevier in Future Healthcare Journal
- Vol. 13 (1) , 100493
Demographic and regional disparities in cancer cachexia-related mortality in the USA from 1999 to 2020 – A retrospective cross-sectional study
- 11 December 2025
- Published by Elsevier in Future Healthcare Journal
- Vol. 13 (1) , 100493
Open AccessDemographic and regional disparities in cancer cachexia-related mortality in the USA from 1999 to 2020 – A retrospective cross-sectional study
- 5 October 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 233, 51-54
Demographic and Regional Trends of Cardiovascular Disease and Obesity-Related Mortality in the United States From 1999 to 2021
- 5 October 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 233, 51-54
Demographic and Regional Trends of Cardiovascular Disease and Obesity-Related Mortality in the United States From 1999 to 2021
- 28 September 2024
- Published by Elsevier in The American Journal of Medicine
- Vol. 138 (2) , 220-227.e5
Demographical and Regional Trends of HIV-Related Mortality Among Young Adults in the United States From 1999 to 2020
- 28 September 2024
- Published by Elsevier in The American Journal of Medicine
- Vol. 138 (2) , 220-227.e5
Demographical and Regional Trends of HIV-Related Mortality Among Young Adults in the United States From 1999 to 2020
- Open Access
- 4 September 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (10) , 5973-5979
Understanding disparities in cardiovascular death rates among older adults with sick sinus syndrome in the US
Background: Sick sinus syndrome (SSS) increases with age, and approximately one in 600 patients above 65 develop this condition. In this study, the authors assessed trends in mortality related to SSS among older adults ≥65 years of age in the United States from 1999 to 2019. Methods: Trends in cardiovascular mortality related to SSS were identified by analyzing the data from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database, where cardiovascular deaths were listed as the underlying cause of death and SSS was listed as the contributing cause of death between 1999 and 2019. Age-adjusted mortality rates (AAMR) per 1,000,000 population were determined. Results: Between 1999 and 2019, a total of 41,615 SSS-related deaths occurred in older adults. Of these, 17,466 (41.9%) were men and 24,149 (58.1%) were women. Although a decline in cardiovascular mortality related to SSS was apparent from 1999 to 2014, a steep rise was noted from 2014 to 2019 [Annual Percentage Change (APC): 2.9%; 95% CI, 1.5–5.7]. Overall AAMRs were highest among White men (AAMR: 55.8; 95% CI, 54.9–56.6), followed by Black men (AAMR: 44.8; 95% CI, 42–47.6), White women (AAMR: 43.3; 95% CI, 42.8–43.9), and Black women (AAMR: 39.4; 95% CI, 37.6–41.2). Rural dwellers had higher AAMRs compared to urban dwellers. Notably, rural dwellers had a period of stability between 2014 and 2019, while an increase in mortality was apparent among urban dwellers during this period. Lastly, states in the 90th percentile displayed approximately two fold higher AAMR compared to those in the bottom 10th percentile. Conclusion: Sick sinus syndrome-related mortality trends have shown a steady rise from 2014 to 2019. Moreover, NH White adults, rural dwellers, and individuals residing in the states among the 90th percentile demonstrated significantly higher AAMRs. Thus, further investigations and actions are required to reverse these rising trends.
- 4 September 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (10) , 5973-5979
Open AccessUnderstanding disparities in cardiovascular death rates among older adults with sick sinus syndrome in the US
Background: Sick sinus syndrome (SSS) increases with age, and approximately one in 600 patients above 65 develop this condition. In this study, the authors assessed trends in mortality related to SSS among older adults ≥65 years of age in the United States from 1999 to 2019. Methods: Trends in cardiovascular mortality related to SSS were identified by analyzing the data from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database, where cardiovascular deaths were listed as the underlying cause of death and SSS was listed as the contributing cause of death between 1999 and 2019. Age-adjusted mortality rates (AAMR) per 1,000,000 population were determined. Results: Between 1999 and 2019, a total of 41,615 SSS-related deaths occurred in older adults. Of these, 17,466 (41.9%) were men and 24,149 (58.1%) were women. Although a decline in cardiovascular mortality related to SSS was apparent from 1999 to 2014, a steep rise was noted from 2014 to 2019 [Annual Percentage Change (APC): 2.9%; 95% CI, 1.5–5.7]. Overall AAMRs were highest among White men (AAMR: 55.8; 95% CI, 54.9–56.6), followed by Black men (AAMR: 44.8; 95% CI, 42–47.6), White women (AAMR: 43.3; 95% CI, 42.8–43.9), and Black women (AAMR: 39.4; 95% CI, 37.6–41.2). Rural dwellers had higher AAMRs compared to urban dwellers. Notably, rural dwellers had a period of stability between 2014 and 2019, while an increase in mortality was apparent among urban dwellers during this period. Lastly, states in the 90th percentile displayed approximately two fold higher AAMR compared to those in the bottom 10th percentile. Conclusion: Sick sinus syndrome-related mortality trends have shown a steady rise from 2014 to 2019. Moreover, NH White adults, rural dwellers, and individuals residing in the states among the 90th percentile demonstrated significantly higher AAMRs. Thus, further investigations and actions are required to reverse these rising trends.
- 1 June 2024
- Published by Edizioni Minerva Medica in Journal of Neurosurgical Sciences
- Vol. 68 (3) , 338-347
Is endovascular treatment alone as effective and safe as that with preceding intravenous thrombolysis for acute ischemic stroke? A meta-analysis of randomized controlled trials
Article: Is endovascular treatment alone as effective and safe as that with preceding intravenous thrombolysis for acute ischemic stroke? A meta-analysis of randomized controlled trials - Journal of Neurosurgical Sciences 2023 Jun 30 - Minerva Medica - Journals
- 1 June 2024
- Published by Edizioni Minerva Medica in Journal of Neurosurgical Sciences
- Vol. 68 (3) , 338-347
Is endovascular treatment alone as effective and safe as that with preceding intravenous thrombolysis for acute ischemic stroke? A meta-analysis of randomized controlled trials
Article: Is endovascular treatment alone as effective and safe as that with preceding intravenous thrombolysis for acute ischemic stroke? A meta-analysis of randomized controlled trials - Journal of Neurosurgical Sciences 2023 Jun 30 - Minerva Medica - Journals
- 23 May 2024
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 15 (6) , 101797
Disparities in the renal cancer mortality between Black and White adults in the United States, 1999–2020
- 23 May 2024
- Published by Elsevier in Journal of Geriatric Oncology
- Vol. 15 (6) , 101797
Disparities in the renal cancer mortality between Black and White adults in the United States, 1999–2020
- 29 April 2024
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 24 (3) , 385-398
Differential Use of Glycoprotein IIb/IIIa Inhibitors with Bivalirudin in Patients with STEMI Undergoing PCI: A Systematic Review and Meta-Analysis
Aim The efficacy and safety of bivalirudin when used concurrently with glycoprotein IIb/IIIa inhibitors (GPI) is uncertain. In this systematic review and meta-analysis, we aimed to evaluate the efficacy and safety of bivalirudin versus heparin in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) and to explore the impact of differential use (greater and balanced) of GPI. Methods Online databases were queried from inception to March 2023 to identify eight randomized controlled trials (n = 22,483) for inclusion. The primary outcomes included all-cause mortality, major bleeding, major adverse cardiovascular events (MACE), and net adverse clinical events (NACE). Secondary efficacy endpoints included cardiac death, reinfarction, stent thrombosis (ST), and stroke. Data were pooled using a random-effects model to derive risk ratios (RRs) and 95% confidence intervals (CIs). Results When compared to heparin, bivalirudin was associated with a significant reduction in all-cause mortality (RR 0.83; 95% CI 0.72–0.97; P = 0.02), major bleeding (RR 0.73; 95% CI 0.57–0.93; P = 0.01), cardiac death (RR 0.79; 95% CI 0.66–0.94; P = 0.01), and NACE (RR 0.80; 95% CI 0.72–0.89; P < 0.0001). However, while the bivalirudin arm showed an increased likelihood of ST in the greater GPI subgroup (RR 1.70; 95% CI 1.13–2.56; P = 0.01), it was associated with a decreased likelihood of ST in the balanced GPI subgroup (RR 0.40; 95% CI 0.24–0.65; P = 0.0003). Conclusion Overall, our findings suggest that bivalirudin may be a more efficacious intervention than heparin for reducing certain adverse events in patients with STEMI undergoing primary PCI.
- 29 April 2024
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 24 (3) , 385-398
Differential Use of Glycoprotein IIb/IIIa Inhibitors with Bivalirudin in Patients with STEMI Undergoing PCI: A Systematic Review and Meta-Analysis
Aim The efficacy and safety of bivalirudin when used concurrently with glycoprotein IIb/IIIa inhibitors (GPI) is uncertain. In this systematic review and meta-analysis, we aimed to evaluate the efficacy and safety of bivalirudin versus heparin in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) and to explore the impact of differential use (greater and balanced) of GPI. Methods Online databases were queried from inception to March 2023 to identify eight randomized controlled trials (n = 22,483) for inclusion. The primary outcomes included all-cause mortality, major bleeding, major adverse cardiovascular events (MACE), and net adverse clinical events (NACE). Secondary efficacy endpoints included cardiac death, reinfarction, stent thrombosis (ST), and stroke. Data were pooled using a random-effects model to derive risk ratios (RRs) and 95% confidence intervals (CIs). Results When compared to heparin, bivalirudin was associated with a significant reduction in all-cause mortality (RR 0.83; 95% CI 0.72–0.97; P = 0.02), major bleeding (RR 0.73; 95% CI 0.57–0.93; P = 0.01), cardiac death (RR 0.79; 95% CI 0.66–0.94; P = 0.01), and NACE (RR 0.80; 95% CI 0.72–0.89; P < 0.0001). However, while the bivalirudin arm showed an increased likelihood of ST in the greater GPI subgroup (RR 1.70; 95% CI 1.13–2.56; P = 0.01), it was associated with a decreased likelihood of ST in the balanced GPI subgroup (RR 0.40; 95% CI 0.24–0.65; P = 0.0003). Conclusion Overall, our findings suggest that bivalirudin may be a more efficacious intervention than heparin for reducing certain adverse events in patients with STEMI undergoing primary PCI.
- Open Access
- 26 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (19) , 6200
Heart Failure Remote Monitoring: A Review and Implementation How-To
Heart failure (HF) is a significant clinical and financial burden worldwide. Remote monitoring (RM) devices capable of identifying early physiologic changes in decompensation have the potential to reduce the HF burden. However, few trials have discussed at length the practical aspects of implementing RM in real-world clinical practice. The present paper reviews current RM devices and clinical trials, focusing on patient populations, outcomes, data collection, storage, and management, and describes the implementation of an RM device in clinical practice, providing a pragmatic and adaptable framework.
- 26 September 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (19) , 6200
Open AccessHeart Failure Remote Monitoring: A Review and Implementation How-To
Heart failure (HF) is a significant clinical and financial burden worldwide. Remote monitoring (RM) devices capable of identifying early physiologic changes in decompensation have the potential to reduce the HF burden. However, few trials have discussed at length the practical aspects of implementing RM in real-world clinical practice. The present paper reviews current RM devices and clinical trials, focusing on patient populations, outcomes, data collection, storage, and management, and describes the implementation of an RM device in clinical practice, providing a pragmatic and adaptable framework.